SCHEMBL23478373

SCHEMBL23478373

NCc1[nH]c2ccncc2c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 4/20 0.51
▸ ACHE P22303 4/20 0.47
▸ MAPK14 Q16539 1/20 0.44
▸ LOXL2 Q9Y4K0 1/20 0.42
▸ PARP1 P09874 1/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ MAPT P10636 5/20 0.39
▸ CHUK O15111 2/20 0.39
▸ FEN1 P39748 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ GABRP O00591 1/20 0.37
▸ GABRD O14764 1/20 0.37
▸ IKBKB O14920 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ TOP1 P11387 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL23452232 0.87 HTR6 (0.42) HTR6ACHEMAPK14LOXL2PARP1
SCHEMBL31558474 0.79 HTR6 (0.51) HTR6ACHEMAPK14PARP1KIF11
SCHEMBL23452429 0.74 ACHE (0.40) HTR6ACHEMAPK14PARP1KIF11
SCHEMBL23473995 0.73 ACHE (0.51) HTR6ACHEMAPK14PARP1KIF11
SCHEMBL29642993 0.70 ACHE (0.78) ACHEPARP1KIF11MAPTCHUK
SCHEMBL972999 0.70 ACHE (0.78) ACHEPARP1KIF11MAPTCHUK
SCHEMBL27447021 0.69 ACHE (0.47) HTR6ACHEMAPK14PARP1KIF11
SCHEMBL23478353 0.69 ACHE (0.47) HTR6ACHEMAPK14PARP1KIF11
SCHEMBL23511225 0.69 ACHE (0.47) HTR6ACHEMAPK14PARP1KIF11
SCHEMBL23478372 0.68 NAMPT (0.43) HTR6KDM4EGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 — — CN disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
WO-2021113682-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 HTR6 4242/4885ACHE 2723/4885MAPK14 2625/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 HTR6 4242/4885ACHE 2723/4885MAPK14 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback